The Department of Health and Human Services has decided not to finalize a proposed rule that would have blocked Medicare and Medicaid payments to any hospital providing gender-affirming care to minors, according to a document obtained by NPR. The change means the administration’s most sweeping plan to curb pediatric gender-affirming services will not take effect in the near term.
Centers for Medicare and Medicaid Services officials told NPR they don’t comment on future rulemaking and said the administration opposes “ideologically driven surgical interventions on vulnerable children.” While surgeries for transgender people under 18 are very rare, the proposed condition-of-participation rule applied broadly to gender-affirming care, which typically includes counseling, puberty blockers and hormone therapy.
Legal and policy experts called the shelving of the rule a setback for the administration’s most aggressive approach, but not a full retreat from its broader agenda. Sam Bagenstos, a University of Michigan law professor who previously served as HHS general counsel under the Biden administration, described the decision as a “victory” for defenders of transgender rights, while cautioning that the administration remains combative on these issues. Bagenstos noted that conditions-of-participation rules have long been used to enforce basic safety and operational standards; proposing one to ban particular medical treatments for a group of patients was unprecedented and raised legal concerns, including potential conflicts with the Medicare Act’s limits on federal control of medical practice within states.
The proposal generated heavy public attention. After being published in December, it drew more than 30,000 public comments. Major medical organizations — including the American Medical Association and the Children’s Hospital Association — urged HHS to withdraw the proposal, arguing that medical evidence supports the safety and effectiveness of puberty blockers and hormones for appropriately selected transgender youth.
The rule’s withdrawal is unlikely to reverse many immediate effects of the administration’s other actions, however. Separate but related steps remain in motion: another Medicaid-centered rule that would bar federal Medicaid reimbursement for transgender pediatric services is in the final stages of review and appears poised to take effect soon. Health Secretary Robert F. Kennedy Jr. also issued a declaration intended to redefine standards of care; that declaration and an accompanying press release have since been removed from the HHS website. A coalition of Democratic-led states sued over the declaration and won a court order blocking it in Oregon; the administration has not appealed that ruling to date.
Enforcement activity has extended beyond rulemaking. The Department of Justice has issued both administrative and criminal subpoenas seeking detailed medical records for transgender youth and employment records for clinicians, though many of those requests have been curtailed by courts. The administration has also reached settlements with some hospitals that, among other provisions, included establishing so-called “detransition” clinics.
These federal actions have coincided with state-level bans: roughly half the states have prohibited aspects of gender-affirming care for minors, while clinics in other states have continued operating. Some hospitals in states that still allow such care have nonetheless curtailed or closed their pediatric gender-affirming programs in recent months, citing federal pressure.
Health policy experts say the decision not to finalize the Medicare/Medicaid conditions-of-participation rule should give hospitals more confidence to resume or continue offering gender-affirming services where state law permits. Katie Keith, director of the Health Policy and the Law Initiative at Georgetown, observed that a finalized federal rule carries a permanence and enforcement threat that other administrative actions lack; its shelving is therefore meaningful for providers. Advocates and policy analysts caution, though, that the administration’s broader campaign against transgender healthcare remains intact, and that the rule could theoretically be revived in the future — the administration’s regulatory agenda lists a potential final action date as late as December 2028.
Advocates for transgender patients welcomed the development while warning that vigilance remains necessary. Kellan Baker, a senior adviser at the Movement Advancement Project, said the administration’s decision to step back from its most extreme proposal is reassuring, but that other tactics to restrict care make the overall threat ongoing.
In short, HHS has paused its most sweeping proposed federal lever to halt pediatric gender-affirming care, but many related federal rules, legal fights and enforcement measures are still active. Hospitals and families seeking clarity will be watching upcoming regulatory steps and court outcomes closely to see whether this signals a narrowing of federal action or a temporary reprieve.